The organoids were from CD45 depleted buffy coat, and showed small and showed diffusely positive pan-cytokeratin and variable AR staining. The established organoid line exhibits a double time of 1 week.
MSK-PCa5 is developed from a patient who developed widespread metastatic disease only five months after prostatectomy for radiographically localized Gleason 4+5 prostate cancer. He had a brief PSA response to ADT and a subsequent sustained PSA response to abiraterone acetate despite radiographic progression of disease.
- Yu Chen, MD, PhD, Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center
- Dong Gao, PhD, formerly at Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center
Gao D, et al. Organoid Cultures Derived from Patients with Advanced Prostate Cancer. Cell, 2014;159(1):176-87.
This organoid cell line may be licensed nonexclusively for research or commercial purposes.
For licensing requests: Alexandra Buga, MBA, Licensing Associate, Office of Technology Development, MSK, 646-888-1078, email@example.com.